ZYBT

Black Swan Sale

50% Off Elite

Get our most powerful screeners, new charting tools, and the fastest ad-
free experience at our best price ever. This deal may never happen again.

Held by: PGJ

Scroll to Statements

Index	-	P/E	61.86	EPS (ttm)	0.03	Insider Own	90.66%	Shs Outstand	47.17M	Perf Week	-4.19%
Market Cap	97.63M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	4.43M	Perf Month	-12.71%
Enterprise Value	116.12M	PEG	-	EPS next Q	-	Inst Own	0.33%	Short Float	3.22%	Perf Quarter	-70.49%
Income	1.57M	P/S	3.77	EPS this Y	-	Inst Trans	0.87%	Short Ratio	0.31	Perf Half Y	-78.83%
Sales	25.89M	P/B	2.50	EPS next Y	-	ROA	2.27%	Short Interest	0.14M	Perf YTD	-57.61%
Book/sh	0.82	P/C	35.50	EPS next 5Y	-	ROE	4.06%	52W High	14.30 -85.59%	Perf Year	-
Cash/sh	0.06	P/FCF	25.49	EPS past 3/5Y	-36.18% -	ROIC	3.97%	52W Low	1.40 47.14%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	20.74	Sales past 3/5Y	-7.94% -	Gross Margin	48.96%	Volatility	7.86% 9.46%	Perf 5Y	-
Dividend TTM	-	EV/Sales	4.49	EPS Y/Y TTM	-64.87%	Oper. Margin	8.80%	ATR (14)	0.30	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.80	Sales Y/Y TTM	-13.57%	Profit Margin	6.06%	RSI (14)	35.20	Recom	-
Dividend Gr. 3/5Y	- -	Current Ratio	1.31	EPS Q/Q	-79.39%	SMA20	-7.09%	Beta	-	Target Price	-
Payout	-	Debt/Eq	0.30	Sales Q/Q	-2.78%	SMA50	-42.41%	Rel Volume	0.09	Prev Close	2.15
Employees	277	LT Debt/Eq	0.02	Earnings	-	SMA200	-65.71%	Avg Volume	453.23K	Price	2.06
IPO	Jan 07, 2025	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	42,781	Change	-4.19%

Jul-03-25 08:30AM	Zhengye Biotechnology Holding Limited Announces Fiscal Year 2024 Financial Results (PR Newswire)
May-23-25 04:05PM	Zhengye Biotechnology Holding Limited Receives NASDAQ Notice Related to Late Filing of Form 20-F (GlobeNewswire) -12.33%
Jan-14-25 12:00PM	Zhengye Biotechnology Holding Limited Announces Full Exercise of Underwriters' Over-Allotment Option (GlobeNewswire)
Jan-08-25 12:00PM	Zhengye Biotechnology Holding Limited Announces Closing of Initial Public Offering (GlobeNewswire) -7.41%
Jan-06-25 05:50PM	Zhengye Biotechnology Holding Limited Announces Pricing of Initial Public Offering (GlobeNewswire)

Zhengye Biotechnology Holding Ltd. engages in the manufacture and sale of veterinary vaccines. It offers a range of vaccines, including vaccines for swine, cattle, goats, sheep, poultry, and dogs. The company was founded on March 24, 2023 and is headquartered in Jilin City, China.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Vanguards Skyline Holdings Lim	Shareholder	Nov 01 '25	Proposed Sale	12.91	2,278,752	29,419,666		Oct 22 04:10 PM
VVAX Holdings Limited	Shareholder	Nov 01 '25	Proposed Sale	2.62	684,996	1,794,690		Oct 22 04:10 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Black Swan Sale

50% Off Elite

Zhengye Biotechnology Holding Ltd

Upgrade your FINVIZ experience